Merck Gets FDA Priority Review for Keytruda in High-Risk, Non-Muscle Invasive Bladder Cancer
02 Décembre 2019 - 01:25PM
Dow Jones News
By Colin Kellaher
Merck & Co. (MRK) on Monday said the U.S. Food and Drug
Administration granted priority review to its supplemental
biologics license application for Keytruda in a form of bladder
cancer.
The Kenilworth, N.J., drug maker said the sBLA seeks accelerated
approval of the cancer drug as monotherapy for the treatment of
patients with Bacillus Calmette-Guerin-unresponsive, high-risk,
non-muscle invasive bladder cancer with carcinoma in-situ with or
without papillary tumors who are ineligible for or have elected not
to undergo removal of bladder.
The FDA grants priority review to medicines that have the
potential to provide significant improvements in the treatment of a
serious disease, and the designation shortens the review
period.
Merck said the FDA's advisory committee on oncologic drugs will
discuss the application at its Dec. 17, adding that it expects an
FDA target action date in January.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
December 02, 2019 07:10 ET (12:10 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Merck (NYSE:MRK)
Graphique Historique de l'Action
De Fév 2024 à Mar 2024
Merck (NYSE:MRK)
Graphique Historique de l'Action
De Mar 2023 à Mar 2024